+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database



Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database



Diseases of the Esophagus 21(8): 685-689



Endoscopic surveillance is recommended for patients with Barrett's esophagus (BE). Based on a large database, gathered from predominantly community-based practices in Germany, we aimed to investigate the time-course of malignant progression and apply these findings to current clinical practice. Data of 1438 patients with BE from a large German BE database were analyzed. Patients with at least one follow-up endoscopy/biopsy were included. Detection of 'malignant Barrett' (either high-grade intra-epithelial neoplasia or invasive adenocarcinoma) was considered as study end-point. Of 1438 patients with BE, 57 patients had low-grade intra-epithelial neoplasia (LG-IN) on initial biopsy and 1381 exhibited non-neoplastic BE. 'Malignant Barrett' was detected in 28 cases (1.9%) during a median follow-up period of 24 months (1-255), accounting for an incidence of 0.95% per patient year of follow-up. The frequency of 'malignant Barrett' was significantly higher (P < 0.001, chi(2)-test) in the LG-IN group (n = 11, 19.3%) compared with the non-neoplastic BE group (n = 17, 1.2%). In the non-neoplastic BE group, 'malignant Barrett' was predominantly found during re-endoscopy within the first year of follow-up (12 of 17; 70.6%), in contrast to the LG-IN group, in which 'malignant Barrett' was observed predominantly after a time exceeding 12 months (8 of 11, 72.7%; P = 0.05, Fisher's exact test). Initial endoscopic evaluations seem to play the most crucial role in managing BE. After 1 year of follow-up, endoscopic surveillance should be focused on patients with LG-IN. In patients with repeatedly proven non-neoplastic BE, elongation of the follow-up intervals to the upper limit of current guidelines, that is, 5 years, might be justified.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052386651

Download citation: RISBibTeXText

PMID: 18847456

DOI: 10.1111/j.1442-2050.2008.00857.x


Related references

Another look at Barrett's esophagus. Current thinking on screening and surveillance strategies. Postgraduate Medicine 110(3): 57-8, 61-2, 65-8, 2001

Increased Familial and Spousal Risk of Barrett's Esophagus in Patients With Barrett's Esophagus: Insights From the Utah Population Database. Gastroenterology 150(4): S68-S69, 2016

Not all of Barrett's esophagus surveillance protocols are created equal: the dangers of retrospective outcome research in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy 80(6): 1203, 2015

Surveillance in Barrett's oesophagus: A critical reappraisal. Scandinavian Journal of Gastroenterology 37(Suppl. 236): 4-8, 2002

M1941 Factors Associated with Detection of Dysplasia in Barrett's Esophagus Surveillance: Analysis of a National Community-Based Gastrointestinal Pathology Database. Gastroenterology 134(4): A-435-A-436, 2008

Tu1079 Adherence to Surveillance Guidelines in Patients With Barrett's Esophagus (Be): Analysis From a Large Multicenter Cohort Study. Gastroenterology 146(5): S-746, 2014

W1051 Adherence to Surveillance Interval Guidelines in Barrett's Esophagus (Be): Analysis From a Large Multicenter Cohort Study. Gastroenterology 138(5): S-640, 2010

Barrett esophagus Management and surveillance strategies. Practical Gastroenterology 18(9 SUPPL ): S24-S27, 1994

Barrett's esophagus: novel strategies for screening and surveillance. Therapeutic Advances in Chronic Disease 10: 2040622319837851, 2019

Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. American Journal of Gastroenterology 95(2): 387-394, 2000

Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus. Gastrointestinal Endoscopy 76(4): 743-755, 2013

Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus. Annals of Translational Medicine 6(13): 259, 2018

Surveillance in Barrett's Esophagus: Utility and Current Recommendations. Gastroenterology Clinics of North America 44(2): 285-297, 2016

Current surveillance and therapeutic options for barrett esophagus. Gastroenterology and Hepatology 4(3): 183-186, 2008

Barrett esophagus. Current situation of the risk and surveillance policy. Presse Medicale 23(40): 1846-1848, 1994